Craft

Advanced
Nyrada

Nyrada

Stock Price

$0.1

2024-10-04

Market Capitalization

$21 M

2024-10-04

Revenue

$3.4 M

FY, 2024

Nyrada Summary

Company Summary

Overview
Nyrada is a preclinical stage drug development company. It specializes in the development of small-molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative, and chronic inflammatory diseases.
Type
Public
Status
Active
Founded
2018
HQ
Gordon, AU | view all locations
Website
https://www.nyrada.com
Cybersecurity rating
Sectors

Table of Contents

Key People

  • John Moore

    John Moore, Non-Executive Chairman

    • James Bonnar

      James Bonnar, CEO

      • Benny Evison

        Benny Evison, Chief Scientific Officer

        • Christopher Cox

          Christopher Cox, Non-Executive Director

          LocationsView all

          1 location detected

          • Gordon, NSW HQ

            Australia

            suite 3, level 4/828 Pacific Hwy

          Nyrada Financials

          Summary Financials

          Revenue (H1, 2025)
          $885.0K
          Gross profit (H1, 2025)
          $885.0K
          Net income (H1, 2025)
          ($2.5M)
          Cash (H1, 2025)
          $5.7M
          EBIT (H1, 2025)
          ($2.5M)

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX